Trinity Biotech to Announce Q3 2024 Financial Results
Trinity Biotech (Nasdaq: TRIB), a commercial stage biotechnology company specializing in diabetes management solutions and human diagnostics, will announce its Q3 2024 financial results on Friday, November 15, 2024. The company will host a conference call at 10:00 AM ET. Trinity Biotech focuses on developing diagnostic systems and has recently entered the wearable biosensor industry through the acquisition of Waveform Technologies Inc.'s biosensor assets. The company sells directly in the US, Germany, France, and the UK, while maintaining distribution partnerships across 75 countries worldwide.
Trinity Biotech (Nasdaq: TRIB), un'azienda biotech in fase commerciale specializzata in soluzioni per la gestione del diabete e diagnostica umana, annuncerà i suoi risultati finanziari del Q3 2024 venerdì 15 novembre 2024. L'azienda terrà una conferenza telefonica alle 10:00 AM ET. Trinity Biotech si concentra sullo sviluppo di sistemi diagnostici e ha recentemente fatto il suo ingresso nel settore dei biosensori indossabili attraverso l'acquisizione delle attività di biosensori di Waveform Technologies Inc. L'azienda vende direttamente negli Stati Uniti, in Germania, Francia e Regno Unito, mantenendo al contempo partnership di distribuzione in 75 paesi in tutto il mondo.
Trinity Biotech (Nasdaq: TRIB), una compañía de biotecnología en etapa comercial especializada en soluciones para la gestión de la diabetes y diagnósticos humanos, anunciará sus resultados financieros del Q3 2024 el viernes 15 de noviembre de 2024. La compañía llevará a cabo una llamada de conferencia a las 10:00 AM ET. Trinity Biotech se enfoca en desarrollar sistemas de diagnóstico y recientemente ha ingresado en la industria de biosensores portátiles a través de la adquisición de los activos de biosensores de Waveform Technologies Inc. La compañía vende directamente en EE. UU., Alemania, Francia y el Reino Unido, mientras mantiene asociaciones de distribución en 75 países de todo el mundo.
트리니티 바이오텍 (Nasdaq: TRIB)은 당뇨 관리 솔루션 및 인체 진단 전문 상업 단계 생명공학 회사로, 2024년 3분기 재무 결과를 2024년 11월 15일 금요일에 발표할 예정입니다. 해당 회사는 동부 표준시로 오전 10시에 콘퍼런스 콜을 개최할 것입니다. 트리니티 바이오텍은 진단 시스템 개발에 집중하고 있으며, 최근 웨어러블 바이오 센서 산업에 Waveform Technologies Inc.의 바이오 센서 자산을 인수함으로써 진출했습니다. 이 회사는 미국, 독일, 프랑스 및 영국에서 직접 판매하며, 전 세계 75개국에 걸쳐 배급 파트너십을 유지하고 있습니다.
Trinity Biotech (Nasdaq: TRIB), une entreprise de biotechnologie en phase commerciale spécialisée dans les solutions de gestion du diabète et le diagnostic humain, annoncera ses résultats financiers du Q3 2024 le vendredi 15 novembre 2024. L'entreprise organisera une conférence téléphonique à 10h00 ET. Trinity Biotech se concentre sur le développement de systèmes de diagnostic et a récemment fait son entrée dans le secteur des biosenseurs portables grâce à l'acquisition des actifs de biosenseurs de Waveform Technologies Inc. L'entreprise vend directement aux États-Unis, en Allemagne, en France et au Royaume-Uni, tout en maintenant des partenariats de distribution dans 75 pays à travers le monde.
Trinity Biotech (Nasdaq: TRIB), ein kommerzielles Biotechnologieunternehmen, das auf Lösungen zur Diabetesbewältigung und menschliche Diagnostik spezialisiert ist, wird am Freitag, den 15. November 2024, seine Finanzergebnisse für das Q3 2024 bekannt geben. Das Unternehmen wird um 10:00 Uhr ET eine Telefonkonferenz abhalten. Trinity Biotech konzentriert sich auf die Entwicklung von Diagnosesystemen und ist kürzlich durch die Übernahme der Biosensor-Aktivitäten von Waveform Technologies Inc. in die Branche der tragbaren Biosensoren eingetreten. Das Unternehmen verkauft direkt in den USA, Deutschland, Frankreich und dem Vereinigten Königreich und pflegt gleichzeitig Vertriebspartnerschaften in 75 Ländern weltweit.
- None.
- None.
Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET
DUBLIN, Ireland, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the third quarter 2024 on Friday, November 15, 2024 and host a conference call at 10:00 AM ET.
Conference Call Dial-In & Webcast Information
| Date: | Friday, November 15, 2024 |
| Time: | 10:00 AM ET |
| United States: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: Webcast: Call me™: | 13750164 click here https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 |
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com
| Contact: | Trinity Biotech plc | LifeSci Partners, LLC |
| Louise Tallon | Eric Ribner | |
| (353)-1-2769800 | (1)-646-751-4363 | |
| E-mail: investorrelations@trinitybiotech.com |
FAQ
When will Trinity Biotech (TRIB) release Q3 2024 earnings?
What time is Trinity Biotech's (TRIB) Q3 2024 earnings call?
What are Trinity Biotech's (TRIB) main business segments?
In which countries does Trinity Biotech (TRIB) sell directly?
